Empagliflozin/Metformin (Synjardy) for Type 2 Diabetes
Empagliflozin/Metformin (Synjardy) for Type 2 Diabetes
December 21, 2015 (Issue: 1484)
The FDA has approved Synjardy (Boehringer Ingelheim/Lilly), a fixed-dose combination of the sodium-glucose
co-transporter 2 (SGLT2) inhibitor empagliflozin
(Jardiance) and metformin (Glucophage, and others),
for treatment of patients with type 2...more
- Invokamet and Xigduo XR – two new combinations for type 2 diabetes. Med Lett Drugs Ther 2014; 56:124.
- American Diabetes Association. Standards of medical care in diabetes – 2015: summary of revisions. Diabetes Care 2015; 38 (Suppl):S4.
- Drugs for type 2 diabetes. Treat Guidel Med Lett 2014; 12:17.
- HU Häring et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2014; 37:1650.
- HU Häring et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2013; 36:3396.
- M Ridderstråle et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2014; 2:691.
- SGLT2 inhibitors: new reports. Med Lett Drugs Ther 2015; 57:139.
- B Zinman et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373:2117.
- SGLT2 inhibitors: drug safety communication – labels to include warnings about too much acid in the blood and serious urinary tract infections. Available at www.fda.gov. Accessed December 10, 2015.
- In brief: ketoacidosis with SGLT2 inhibitors. Med Lett Drugs Ther 2015; 57:94.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Empagliflozin/Metformin (Synjardy) for Type 2 Diabetes
Article code: 1484c
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
